These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 6664231

  • 1. Naloxone increases vasopressin secretion from the neurointermediate lobe of the hypophysis of the rat: search for the endogenous agonist.
    Knepel W, Nutto D, Meyer DK.
    Life Sci; 1983; 33 Suppl 1():499-502. PubMed ID: 6664231
    [Abstract] [Full Text] [Related]

  • 2. The effect of naloxone on vasopressin release from rat neurohypophysis incubated in vitro.
    Knepel W, Meyer DK.
    J Physiol; 1983 Aug; 341():507-15. PubMed ID: 6620188
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of various opioid peptides on vasopressin and oxytocin release from the rat pituitary in vitro.
    Maysinger D, Vermes I, Tilders F, Seizinger BR, Gramsch C, Höllt V, Herz A.
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Dec; 328(2):191-5. PubMed ID: 6152015
    [Abstract] [Full Text] [Related]

  • 4. Dynorphin A inhibits and naloxone increases the electrically stimulated release of oxytocin but not vasopressin from the terminals of the neural lobe.
    Bondy CA, Gainer H, Russell JT.
    Endocrinology; 1988 Apr; 122(4):1321-7. PubMed ID: 2894296
    [Abstract] [Full Text] [Related]

  • 5. Levels of dynorphin-(1-13) immunoreactivity in rat neurointermediate pituitaries are concomitantly altered with those of leucine enkephalin and vasopressin in response to various endocrine manipulations.
    Höllt V, Haarmann I, Seizinger BR, Herz A.
    Neuroendocrinology; 1981 Dec; 33(6):333-9. PubMed ID: 6275285
    [Abstract] [Full Text] [Related]

  • 6. Endogenous opioids inhibit the in vitro release of endogenous dopamine preferentially in the neural lobe of the rat neurointermediate lobe.
    Racké K, Böhm E, Hurth S, Muscholl E.
    Life Sci; 1986 May 12; 38(19):1749-56. PubMed ID: 3702604
    [Abstract] [Full Text] [Related]

  • 7. Inhibition by prostaglandin E2 of the release of vasopressin and beta-endorphin from rat pituitary neurointermediate lobe or medial basal hypothalamus in vitro.
    Knepel W, Nutto D, Vlaskovska M, Kittel C.
    J Endocrinol; 1985 Aug 12; 106(2):189-95. PubMed ID: 3160802
    [Abstract] [Full Text] [Related]

  • 8. Effects of opioid agonists and antagonists on oxytocin and vasopressin release in vitro.
    Bicknell RJ, Chapman C, Leng G.
    Neuroendocrinology; 1985 Aug 12; 41(2):142-8. PubMed ID: 2864649
    [Abstract] [Full Text] [Related]

  • 9. Differential inhibitory action by morphine on the release of oxytocin and vasopressin from the isolated neural lobe.
    Clarke G, Patrick G.
    Neurosci Lett; 1983 Aug 29; 39(2):175-80. PubMed ID: 6633948
    [Abstract] [Full Text] [Related]

  • 10. Opioid-noradrenergic interactions in the neurohypophysis. I. Differential opioid receptor regulation of oxytocin, vasopressin, and noradrenaline release.
    Zhao BG, Chapman C, Bicknell RJ.
    Neuroendocrinology; 1988 Jul 29; 48(1):16-24. PubMed ID: 2845291
    [Abstract] [Full Text] [Related]

  • 11. Do opioid peptides modulate, at the level of the nerve endings, the release of neurohypophysial hormones?
    Nordmann JJ, Dayanithi G, Cazalis M.
    Exp Brain Res; 1986 Jul 29; 61(3):560-6. PubMed ID: 3514253
    [Abstract] [Full Text] [Related]

  • 12. GABAA and GABAB receptor-mediated inhibition of release of 5-hydroxytryptamine in the intermediate lobe of the rat pituitary gland.
    Racké K, Holzbauer M, Sharman DF, Cooper TR.
    Neuroscience; 1987 Nov 29; 23(2):679-84. PubMed ID: 2830560
    [Abstract] [Full Text] [Related]

  • 13. Ontogenetic development of the pro-enkephalin B (= pro-dynorphin) opioid peptide system in the rat pituitary.
    Seizinger BR, Liebisch DC, Grimm C, Herz A.
    Neuroendocrinology; 1984 Nov 29; 39(5):414-22. PubMed ID: 6151128
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mercuric chloride inhibition of vasopressin release from the isolated neurointermediate lobe of the rat pituitary.
    Clifton GG, Pearce CJ, Elliot K, Wallin JD.
    Biochim Biophys Acta; 1986 Jul 11; 887(2):189-95. PubMed ID: 3719009
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Contrasting interactions of the locus coeruleus as compared to the ventral noradrenergic bundle with CNS and pituitary pools of vasopressin, dynorphin and related opioid peptides in the rat.
    Millan MJ, Millan MH, Członkowski A, Herz A.
    Brain Res; 1984 Apr 30; 298(2):243-52. PubMed ID: 6144361
    [Abstract] [Full Text] [Related]

  • 18. Opiate receptor subtypes in the rat hypothalamus and neurointermediate lobe.
    Stojilković SS, Dufau ML, Catt KJ.
    Endocrinology; 1987 Jul 30; 121(1):384-94. PubMed ID: 3036471
    [Abstract] [Full Text] [Related]

  • 19. Coexisting peptides in hypothalamic neuroendocrine systems: some functional implications.
    Bondy CA, Whitnall MH, Brady LS, Gainer H.
    Cell Mol Neurobiol; 1989 Dec 30; 9(4):427-46. PubMed ID: 2575930
    [Abstract] [Full Text] [Related]

  • 20. Isoprenaline and forskolin increase evoked vasopressin release from rat pituitary.
    Racké K, Rothländer M, Muscholl E.
    Eur J Pharmacol; 1982 Aug 13; 82(1-2):97-100. PubMed ID: 6889972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.